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Abstract
Background: Obesity can be considered a global public health problem that affects virtually all countries
worldwide and results in greater use of healthcare services and higher healthcare costs. We aimed to
describe average monthly household medicine expenses according to source of funding, public or private,
and to estimate the influence of the presence of obese residents in households on total medicine expenses.
Methods: This study was based on data from the 2008–2009 Brazilian Household Budget Survey, with a representative
population sample of 55,970 households as study units. Information on nutritional status and medicines acquired and
their cost in the past 30 days were analyzed. A two-part model was employed to assess the influence of obesity
on medicine expenses, with monthly household medicine expenses per capita as outcome, presence of obese in
the household as explanatory variable, and adjustment for confounding variables.
Results: Out-of-pocket expenses on medicines were always higher than the cost of medicines obtained through
the public sector, and 32 % of households had at least one obese as resident. Monthly household expenses on
medicines per capita in households with obese was US$ 20.40, 16 % higher than in households with no obese.
An adjusted model confirmed that the presence of obese in the households increased medicine expenses.
Conclusion: Obesity is associated with additional medicine expenses, increasing the negative impact on
household budgets and public expenditure.
Keywords: Costs, Obesity, Pharmaceuticals, Health systems, Household budget survey, Public health,
Epidemiology
Background
Obesity can be considered a global public health problem
that affects virtually all countries worldwide, including
both developing and developed nations [1]. According to
global estimates, between 1980 and 2008, obesity rates
rose from 7.9 to 13.8 % among women and from 4.8 to
9.8 % in men [2]. In Brazil, obesity is increasing, according
to national surveys conducted since the 1970s, across all
age groups and genders [3]. In the adult population of
state capitals, obesity has affected an additional 1 % of the
population every year, since the mid-2000s [4].
Obesity, and the higher risk for several associated
non-communicable diseases (NCDs), results in greater
use of healthcare services and higher healthcare costs
[5]. Since the 1990s, researchers in developed countries
have analysed the cost of obesity and recognized its sig-
nificant economic impact on health systems [6–9]. In
Brazil, there are few data about this topic and all refer
to the perspective of society. The first study investi-
gated the burden of hospitalization due to obesity in
2001 [10] and later two studies evaluated the direct
costs associated to outpatient and inpatient care of
obesity based on data from public health information
systems (2008–2011). These studies showed the high
cost of overweight and/or obesity for the Brazilian
national health system (Sistema Único de Saúde - SUS)
[11, 12] used by 75 % of the population [13, 14].
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These studies, however, did not present data on
medicine expenses. The available databases provide
limited information on the utilization and cost of these
products in the public health system [12] and private
expenses, corresponding to out-of-pocket payments by
the population, are not included at all. Given the
current gaps in knowledge, and the availability of data
regarding expenses on medicines in the Brazilian
Household Budget Survey, the objective of the present
study was to describe average monthly per capita
household expenses on medicines and to estimate the
influence of the presence of obese residents in house-
holds on total household expenses on medicines.
Methods
Data source and sample
The present study used data of the Household Budget
Survey (HBS) conducted by the Brazilian Institute of
Geography and Statistics (IBGE) between May 2008 and
May 2009.
This was a population-based study involving 55,970
Brazilian households, based on a complex sample plan
using two-stage cluster sampling, with random selection
of census sectors during the first stage and of house-
holds in the second stage. For selection of census sec-
tors, the 12,800 sectors present in the Master Sample of
Household Surveys were grouped to obtain household
strata with high geographic and socioeconomic homo-
geneity. The geographic location of the sector (region,
state, and urban or rural area), as well as internally in
each geographic locus, and the spectrum of socioeco-
nomic variation of the families (based on the income of
head of household), were considered for this grouping.
The number of households randomly selected from each
stratum was proportional to the total number of house-
holds in the stratum. Interviews with households in each
stratum were distributed uniformly over the four quar-
ters of the year in order to represent the seasonal varia-
tions of the expenditures [15].
Data collection
The information from the HBS relevant to the objectives
of this study were medicine expenses (monetary or non-
monetary), nutritional status of household residents and
sociodemographic data.
Medicine expenses were registered in a specific instru-
ment, to be answered by residents aged 10 years or
older, and include medicine expenses of all members of
the household. All medicines referred in the survey were
included in the study.
The reference period for expenses on medicines was
the 30 days previous to the interview. Information was
collected for acquisition modes (monetary or non-
monetary), cost, place of acquisition and characteristics
of the product (brand name, generic, plant and herbal
medicine, compounded, or homeopathic).
Regarding non-monetary expenses, i.e. medicines
distributed without charge by the health system, their
cost was estimated by the residents based on local
market prices [15].
All individuals residing in the household were in-
cluded in the nutritional status assessment, excluding
pregnant women (n = 188,461). Weights and heights
were measured using standard techniques by the re-
searcher and recorded in specific questionnaires, along
with characteristics of the residents and of the house-
hold. Weight was measured using portable electronic
scales with a maximum capacity of 150(kg), and gradu-
ations of 100(g). The value obtained was recorded in
kilograms. Height was expressed in centimetres (cm)
using length as the measure in children aged between
zero and 23 months and stature in individuals aged
24 months or older. In order to measure length, infant
anthropometres were used with a capacity of up to
105 cm and a scale in millimetres, whereas stature was
measured using portable stadiometres with a 200 cm-
long retractable tape measure, accurate to the nearest
0.1 cm [3].
Assessment of spending on medicines
Although medicine expenses are related to individual
needs, the household was the study unit, considering
that these expenses rarely depend only on an individual
decision [16] but are related to family dynamics [17] and
only individuals aged 10 years or older reported ex-
penses, and the children’s expenses were reported by
other members of the household.
Total spending on medicines was divided in expenses
in the public sector (obtained in the SUS and in pharma-
ceutical assistance programs) and in the private sector
(paid for out-of-pocket). To this end, information of
product acquisition (monetary or non-monetary) and
place of obtainment were used. The deflated amount of
the spending was calculated, using as reference January
15th, 2009 and the Extended Consumer Price Index
(Índice Nacional de Preços ao Consumidor Amplo-IPCA),
in order to correct the absolute and relative shifts in prices
during the year [15]. Expenses in Reals were converted
into US dollars using a purchasing power parity basis
(PPP 2009: US$ 1.00 = RS 1.63) [18].
Household expenses on medicines were summed up
and divided by the number of residents, obtaining
monthly per capita household medicine expenses.
Assessment of nutritional status
Based on weight and height measurements taken, body
mass index (BMI) was calculated for adults and elderly,
whereas BMI-for-age was calculated for children and
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adolescents and expressed as z-score. The nutritional
status of individuals was classified according to recom-
mendations by the World Health Organization (WHO)
for each age group. Obesity was defined as a BMI of
above 30 kg/m2 for adults and elderly, +3 z-scores for
children under 5 years of age, and +2 z-scores for chil-
dren and adolescents (5–19 years) [19–21].
Considering the households as study units, the propor-
tion of households containing at least one obese resident
(presence of obese residents) was calculated.
Data analysis
Sociodemographic characteristics were expressed per
quintiles of per capita household income. A descriptive
analysis of monthly per capita household expenses on
medicines was performed, for the public and private sec-
tor, and the proportion of households with at least one
obese resident, according to sociodemographic variables.
Monthly per capita household expenses on medicines,
according to source of funding and total spending, were
described according to the presence of obese in the
households. Households with and without obese were
compared with the difference of means tests.
The association between the presence of obese in
household and monthly per capita expenses on medi-
cines was analysed using two-part model (TPM), a
recommended method in the analysis of cost of obes-
ity data, as it takes into account that a proportion of
the population does not have health expenditures at
all [22–25]. In our case, 17 % of households did not
incur any expenses in the 30 days before the survey.
According to this method one equation predicts the
probability that a person has any expenditure, using
logistic regression, and a second equation predicts the
level of expenditure, using linear regression [23, 24].
Both equations were adjusted for social and family
characteristics that influence the presence of obese
residents and expenses on medicines in households
such as: proportion of children aged under 2 years,
children aged 2 to 9, adolescents, elderly and of women in
the household, presence of pregnant women in the house-
hold, region, area, and monthly household income per
capita. The predicted coefficient value, considering the co-
efficients of the two equations, was calculated.
All analyses were carried out using the statistics pack-
age Stata/SE version 12.1 (Stata Corp., College Station,
USA) in the survey module, which considers the effects
of complex sampling and enables the extrapolation of
results for the Brazilian population, considering a 95 %
confidence interval and 5 % significance level.
Ethical aspects
The study was approved by the Research Ethics Com-
mittee of School of Public Health, University of São
Paulo (Process number 2292). This study utilized data
from the HBS 2008–2009, collected by the IBGE, a public
database available online. The information contained in
the database is confidential since specific data about each
household such as identification of the household mem-
bers, address and telephone are excluded.
Results
A total of 55,970 Brazilian households were studied. Of
this total, 84.4 % were situated in the urban area and
67.1 % in the Mid-South of the country. The house-
holds had an average of 3.3 residents, 3.2 % of whom
were children under 2 years, 8.9 % children aged 2–
9 years, 14.1 % adolescents, 11.6 % elderly, and 51.8 %
women. Average monthly household income per capita
was US$ 645 and 3.4 % of the income was dedicated to
cover monthly private expenses on medicines (out-of-
pocket) (Table 1).
Considering all households, 17 % (n = 9,730) did not
have any expenses on medicines in the last month (data
not shown). Out-of-pocket expenses on medicines were
higher than for those obtained through the public sector,
in urban and rural areas, all regions and income groups.
Out-of-pocket expenses exceeded public expenses even
in the 20 % poorest stratum of the population (Table 2).
Of all the households studied, 32.1 % had at least one
obese individual in the household, and this percentage
was higher in the urban area, in the Mid-South of the
country and in the intermediate income levels (Table 3).
In the Brazilian population, considering all age groups,
the prevalence of obesity was 13.2 % (data not shown).
Average monthly per capita household medicine
expenses in households with obese residents were
US$20.40, 16 % higher than expenses in households
with no obese individuals. Out-of-pocket expenses on
medicines were 11 % higher in households with at
least one obese (Table 4).
Adjusted and predicted coefficients showed a statisti-
cally significant positive association for higher expenses
on medicines attributable to the presence of obese resi-
dents in the household. After adjusting for confounding
variables, results showed that the presence of obese in
the households was associated with 19 % higher monthly
expenses on medicines per capita compared to house-
holds with no obese residents (Table 5).
Discussion
Based on data representative of the Brazilian population,
32 % of households had at least one obese individual in
the family unit and expenses on medicines were higher
in households with obese residents.
No results of studies similar to this one were found,
with the household as the analytic unit instead of indi-
viduals, and with data on expenses on medicines in the
Canella et al. BMC Public Health  (2016) 16:54 Page 3 of 8
public sector and out-of-pocket expenditures. Our results
are consistent with data in studies measuring the influence
of obesity on healthcare and medicine expenses in the pri-
vate or public sector, demonstrating the contribution of
obesity in increased expenses on medicines.
A literature review including studies conducted in sev-
eral countries worldwide estimated that direct medical
costs of obese individuals are around 30 % greater than
for normal weight subjects (BMI ≤ 25 kg/m2) [26]. This
difference is higher, but similar to the figure found in
this study (19 %) when comparing households with and
without obese residents.
A study conducted in Italy in 2001–2002 with
adults observed that medicine expenses in the Italian
health system for treatment of obese individuals were
153 % greater than for normal weight individuals
(BMI 18.5–24.9 kg/m2) (335.64 Euros/year × 132.71
Euros/year, respectively) [27].
Table 2 Distribution of medicine expenses, according to public and private sector and sociodemographic variables. Brazil,
2008–2009
Variables Monthly household medicine expenses per capitaa
Public Sector (obtained in the SUS) Private Sector (paid for out-of-pocket) Total
US$ % spent on medicines US$ % spent on medicines US$
Area
Rural 2.32 16.13 9.39 83.87 11.71
Urban 3.32 12.01 16.41 87.99 19.73
Regions
North and Northeast 1.71 11.42 9.31 88.58 11.01
Mid-South 3.88 13.23 18.26 86.77 22.14
Household income per capita (US$)
1st quintile 1.01 16.37 4.34 83.63 5.35
2nd quintile 2.13 15.36 8.04 84.64 10.17
3rd quintile 3.46 15.33 12.18 84.67 15.64
4th quintile 4.08 11.51 18.16 88.49 22.24
5th quintile 5.17 5.11 33.82 94.89 38.99
Brazil 3.17 12.64 15.31 87.36 18.48
aValues in dollars (US$)
Table 1 Household distribution of sociodemographic characteristics, by quintiles of household income. Brazil, 2008–2009
Variables Quintiles of household income per capita (mean values) Brazil
1st 2nd 3rd 4th 5th
Area (%)
Rural 31.1 18.5 14.6 9.0 4.7 15.6
Urban 68.9 81.5 85.4 91.0 95.3 84.4
Region (%)
North and Northeast 61.4 40.2 28.3 19.0 15.8 33.0
Mid-South 38.6 59.8 71.7 81.0 84.2 67.1
Number of dwellers in households 4.5 3.7 3.0 2.8 2.5 3.3
Proportion of children under 2 years of age in family unit (%) 6.4 4.0 2.5 1.9 1.4 3.2
Proportion of children 2–9 years of age in family unit (%) 17.2 11.2 6.9 5.6 3.7 8.9
Proportion of adolescents (10–19 years) in family unit (%) 23.0 18.1 12.3 9.7 7.5 14.1
Proportion of elderly (65 years or older) in family unit (%) 2.6 7.1 16.8 15.9 15.7 11.6
Proportion of women in family unit (%) 50.7 51.3 51.6 52.7 52.6 51.8
Monthly household income per capita (US$) 97.22 213.22 353.00 591.38 1968.82 644.70
Proportion of monthly household income per capita dedicated to
monthly medicine expenses per capita (out-of-pocket expenditure) (%)
5.1 3.6 3.3 2.9 2.0 3.4
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A reference study for the US presented payer and
service-specific estimates for 2008 of annual medical
spending attributable to obesity, and found an in-
crease in adult per capita prescription drugs spending
attributable to obesity of USD$ 568 (8.3 % increase),
for all payers (Medicare, Medicaid and Private) [28].
Prescription expenses of Medicare beneficiaries in-
creased progressively with rising BMI. Individuals that
were obese class I (BMI 30–34.9 kg/m2), class II
(BMI 35–39.9 kg/m2) and class III (BMI ≥ 40 kg/m2)
had spending that was 34, 46 and 69 % higher, re-
spectively, compared to spending of normal weight
individuals. After adjusting for confounding variables,
the annual mean spending of obese class I individuals
was US$ 267 higher than those of normal weight
[29]. Another North American study involving indi-
viduals aged from 6 to 85 years analysed obesity-
related healthcare expenditures with specific analysis
of spending on medicines. The results showed that
adjusted annual expenditures on medicines among
obese females and males were 76 and 59 % higher, re-
spectively, than for normal weight individuals of the
same gender [30].
The differences in the magnitude of medicine expenses
of obese individuals in comparison to normal weight
subjects observed in the studies are due to differences in
study perspective, information sources, age and income
level of individuals, country of origin as well as health-
care systems characteristics.
Regarding the source of funding for medicines, lower
expenses on medicines received in the public sector
(SUS and pharmaceutical assistance programs) (around
12 % of total expenses) compared to out-of-pocket ex-
penses were observed. This may be explained by two
factors: the investment from the public sector reaches
families through freely distributed medicines in health
services or co-payment schemes in pharmacies, leading
to substantial underestimation by the families of the
expenses funded by the public sector; but also by the
limitations in access to medicines in the SUS. The co-
payment scheme involves payment of the medicines by
the Federal Government (90 %) to pharmacies and drug
stores from the private network accredited to the “Aqui
tem Farmácia Popular” program. These participating
pharmacies are rapidly spreading in the country and sell
low-cost medications for hypertension, diabetes, choles-
terol, asthma, rhinitis, Parkinson’s disease, osteoporosis,
glaucoma and birth control [31, 32].
The results of this study are relevant since in develop-
ing countries the spending on medicines accounts for
24–66 % of national expenditure on healthcare [33]. In
Brazil, household out-of-pocket expenses on medicines
were estimated as representing 35 % of healthcare ex-
penses, a percentage substantially higher in lower in-
come families [34]. A study conducted in 2008 involving
a representative sample of Brazilian households found
that, among individuals using the SUS, prevalence of ac-
cess to the full range of medicines prescribed was less
than 50 % [35]. This finding strengthens the hypothesis
that there is still limited access to medicines in the
public health system, resulting in higher out-of-pocket
spending on health in poorer families, spending which
Table 3 Distribution of proportion of households with obese
individuals, according to sociodemographic variables. Brazil,
2008–2009
Variables Proportion of households with
at least one obese individual
(%) (presence of obese in
household)a,b
Area
Rural 28.63
Urban 32.75
Regions
North and Northeast 29.42
Mid-South 33.43
Household income per capita (US$)
1st quintile 30.36
2nd quintile 32.14
3rd quintile 32.67
4th quintile 33.48
5th quintile 31.89
Brazil 32.11
aIncludes individuals of all age groups and excluding pregnant women
bClassification according to recommendations by the World Health
Organization for each age group: BMI above 30 kg/m2, for adults and elderly,
+3 z-scores, for children under 5 years, and +2 z-scores, for children and
adolescents (5–19 years)
Table 4 Average of medicine expenses, according to the presence of obese in households. Brazil, 2008–2009
Presence of obese
in householda,b
Monthly household medicine expenses per capitac
Public Sector (obtained in the SUS) Private Sector (paid for out-of-pocket) Total medicine expenses
No 2.77 14.80 17.57
Yes 4.01 16.39* 20.40*
*p < 0.05
aIncludes individuals of all age groups and excluding pregnant women
bClassification according to recommendations by the World Health Organization for each age group: BMI above 30 kg/m2, for adults and elderly, +3 z-scores, for
children under 5 years, and +2 z-scores, for children and adolescents (5–19 years)
cValues in dollars (US$)
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has been characterized as catastrophic due to its nega-
tive impact on the family economic situation [36].
The present study used data from household budget
surveys and therefore has limitations inherent to this
type of data. The information on acquisition of medi-
cines in the HBS refers to the preceding 30 days. Conse-
quently, spending on acute, unstable or seasonal diseases
may have been underestimated in the survey. On the
other hand, besides being a disease in itself, obesity con-
stitutes a risk factor for a variety of different NCDs [12]
for which spending on medicines may be more accur-
ately reported. In addition, there is also the possibility of
under-reporting of medicines obtained by individuals,
particularly those provided by healthcare services. Due
to these limitations, the results of the present study may
be underestimated and the actual spending on medicines
may be higher.
The questionnaire for collection of data on the acqui-
sition of medicines was filled out by all individuals over
the age of 10 residing at the sampled households. How-
ever, the intra household distribution of the use of medi-
cines remains unknown, given that a situation may occur
where one individual purchases medicines for other mem-
bers of the household or for children under the age of 10.
For this reason and considering that spending decisions
are part of family dynamics [17], the household and not
the individual, was the study unit and basis for the calcula-
tion of average per capita medicine expenses. The influ-
ence of factors such as age of the individuals, gender and
household income [27, 35, 37, 38], on medicine expenses,
were controlled by adjusting for these confounding vari-
ables in the analysis. Additional analyses considering the
proportions of obese individuals in the household as ex-
posure were carried out, but the results were similar to
considering only the presence of one or more obese indi-
viduals. The results without discriminating the effect of
the the intensity of obesity on household expenses are
more straightforward and useful.
Table 5 Association between medicine expenses and presence of obese in households. Brazil, 2008–2009
Variables Monthly household per capita medicine expenses
Adjusted analyses
Logistic regressionc Linear regressiond Predicted (TPM combined)
Coefficient Coefficient Coefficient
[95 % CI] [95 % CI] [95 % CI]
Presence of obese in householda,b (0 = no; 1 = yes) 0.29 3.15 3.35
[0.21; 0.37] [1.03; 5.28] [1.54; 5.15]
Proportion of elderly (65 years or older) 0.84 32.30 29.26
[0.66; 1.02] [28.21; 36.40] [25.78; 32.73]
Proportion of children under 2 years 1.71 −14.30 −7.96
[1.29; 2.12] [−18.38;−10.23] [−11.51;−4.41]
Proportion of children (2–9 years) 0.37 −22.31 −17.93
[0.13; 0.61] [−25.51;−18.87] [−20.87;−14.98]
Proportion of adolescents (10–19 years) 0.26 −17.87 −14.45
[0.07; 0.45] [−25.74;−18.87] [−16.99;−11.92]
Proportion of women 0.95 11.82 12.25
[0.78; 1.13] [8.45; 15.19] [9.36; 15.14]
Presence of pregnant women 0.12 3.18 2.96
[−0.08; 0.32] [−6.11; 12.48] [−4.90; 10.83]
Monthly per capita household income 0.00 0.01 0.01
[0.00; 0.00] [0.01; 0.01] [0.00; 0.01]
Region (0 = North and Northeast; 1 = Mid-South) 0.00 6.31 5.33
[−0.08; 0.08] [5.37; 7.25] [4.50; 6.15]
Area (0 = rural; 1 = urban) 0.11 1.82 1.80
[0.01; 0.21] [0.72; 2.93] [0.83; 2.77]
aIncludes individuals of all age groups and excluding pregnant women
bClassification according to recommendations by the World Health Organization for each age group: BMI above 30 kg/m2, for adults and elderly, +3 z-scores, for
children under 5 years, and +2 z-scores, for children and adolescents (5 –19 years)
cn = 55,970
dn = 46,240
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Conclusions
Considering an already unfavourable context, this study
revealed that obesity, based on the presence of obese
residents in households, is associated with additional
medicine expenses, increasing the negative impact on
household budgets and public expenditure. Strategies for
the prevention of obesity should be strengthened or im-
plemented, along with actions targeting care, treatment
and access to medicines of obese individuals. Among
other outcomes, these initiatives could reduce the im-
pact of obesity on household expenses on medicines.
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